Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., will participate in a technologies panel at the Cowen 2^nd Annual Novel Mechanisms in Neuropsychiatry Summit on Monday, September 19, 2022 at 4:15 p.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit.

About Alto Neuroscience

Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals’ biology impact how they respond to treatment. Alto’s human data-driven platform measures brain biomarkers including EEG activity and behavioral patterns, wearable data, genetics, and other factors, to match each patient with the right Alto therapy. The company’s clinical-stage pipeline includes drug candidates being studied in mental health conditions targeting cognition, emotion, and sleep processes. For more information, visit https://www.altoneuroscience.com or follow us on Twitter.